Glenmark Outlicenses Asthma Drug

Glenmark Pharmaceuticals SA, a subsidary of Glenmark Pharmaceuticals Ltd (GPL), has outlicensed its asthma drug GRC 3886 for $53 million to Teijin Pharma which would allow the latter to develop and market the drug in Japan. GRC 3886 is an orally available PDE4 inhibitor discovered by Glenmark which can be used for the treatment for chronic obstructive pulmonary disorder (COPD) and asthma.

The Economic Times (http://economictimes.indiatimes.com/articleshow/1089016.cms)